OsteoarthritisPhase 2ITICNCT00565812
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee
A Phase 2 study testing SD-6010 in people with Osteoarthritis, run by Pfizer at 183 sites in 14 countries.
Trial summary
The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. Read more about this study
- Who is it for?
- Ages 40 to 99 years
- Conditions the study is for
- Osteoarthritis
- What is being tested?
- SD-6010
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,457 participants
- Where
- 183 sitesin 14 countries
- Study dates
- Nov 2007to Nov 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects aged >= 40 years with a BMI >= 25 and <= 40 kg/m2
- In the past, has been diagnosed with knee OA
- Radiographic evidence of OA in the study knee
Who cannot join
- A diagnosis of any other rheumatic disease
- Current conditions in the study knee that would confound efficacy
- Selected, traditional clinical safety and laboratory parameters
Trial locations and contacts
183 sites in 14 countries.
183 sites in 14 countries
United States120 sites
Ronald Keith Stegemoller, American Health Network
Avon, Indiana, 46123
Advantage Diagnostics
Beachwood, Ohio, 44122
East Penn Rheumatology Associates, PC
Bethlehem, Pennsylvania, 18015
Brookwood Internists, P.C.
Birmingham, Alabama, 35209
Greystone Medical Center
Birmingham, Alabama, 35242
Miray Medical Center
Brockton, Massachusetts, 02301
Kernodle Clinic Inc.
Burlington, North Carolina, 27215
Cadillac Clinical Research, LLC, located at Great Lakes Family Care
Cadillac, Michigan, 49601
Med Center
Carmichael, California, 95608
Rheumatology Associates
Charleston, South Carolina, 29407
Preventive Medicine
Chicago, Illinois, 60611
Rehabilitation Institue of Chicago
Chicago, Illinois, 60611
Mercy Medical Group/Woodlake Research
Clarkson Valley, Missouri, 63011
Rapid Medical Research, Inc.
Cleveland, Ohio, 44122
Columbus Clinical Research, Inc.
Columbus, Ohio, 43213
Optimed Research, LLC
Columbus, Ohio, 43235
College Hospital Costa Mesa
Costa Mesa, California, 92627
NeuroNetwork Trials
Costa Mesa, California, 92627
Baylor Research Institute
Dallas, Texas, 75231
Metroplex Clinical Research Center
Dallas, Texas, 75231
Denver Internal Medicine Group
Denver, Colorado, 80209
Mountain View Clinical Research, Inc.
Denver, Colorado, 80209
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Regional Clinical Research, Inc.
Endwell, New York, 13760
NorthShore University HealthSystem
Evanston, Illinois, 60201
Med Investigations, Inc.
Fair Oaks, California, 95628
Advanced Radiology Consultants
Fairfield, Connecticut, 06824
Phase III Clinical Research
Fall River, Massachusetts, 02720
Fall River Clinical Research
Fall River, Massachusetts, 02721
Internal Medicine Associates
Fargo, North Dakota, 58103
Lillestol Research, LLC
Fargo, North Dakota, 58103
Parkway Medical Group
Fayetteville, Tennessee, 37334
Arthritis and Osteoporosis Treatment and Research Center
Flowood, Mississippi, 39232
Southeastern Arthritis Center
Gainesville, Florida, 32607
Southeastern Imaging & Diagnostics
Gainesville, Florida, 32607
Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute
Gainesville, Florida, 32607
NorthShore University HealthSystem
Glenview, Illinois, 60025
New West Physicians Clinical Research
Golden, Colorado, 80401
Southeastern Radiology
Greensboro, North Carolina, 27407
PharmQuest
Greensboro, North Carolina, 27408
Radiant Research, Inc.
Greer, South Carolina, 29651
Clinical Investigation Specialists, Inc.
Gurnee, Illinois, 60031
East-West Medical Research Institute
Honolulu, Hawaii, 96814
Jacksonville Center for Clincal Research
Jacksonville, Florida, 32216
Memorial Hospital Jacksonville
Jacksonville, Florida, 32216
Dynamic Clinical Research, Inc.
Kansas City, Missouri, 64114
Joan Prouty Moore, MD
Kansas City, Missouri, 64114
Orthopaedic and Occupational Medicine
Kansas City, Missouri, 64114
The Center for Pharmaceutical Research, P.C.
Kansas City, Missouri, 64114
Clinical Investigation Specialists, Inc.
Kenosha, Wisconsin, 53142
Holston Medical Group
Kingsport, Tennessee, 37660
D. Matthew Sellers MD PC
Knoxville, Tennessee, 37920
Affiliated Clinical Research, Inc.
Las Vegas, Nevada, 89106
Office of Michael Mall, M.D.
Las Vegas, Nevada, 89109
Nevada Imaging Centers
Las Vegas, Nevada, 89117
Nevada Imaging Centers
Las Vegas, Nevada, 89118
Office of Danka Michaels, MD
Las Vegas, Nevada, 89128
Office of Stephen H. Miller, MD
Las Vegas, Nevada, 89144
Office of Manoj Kohli, M.D.
Lexington, Kentucky, 40517
Martin Bowen Hefley Orthopedics
Little Rock, Arkansas, 72205
Teton Research, LLC
Little Rock, Arkansas, 72205
L-MARC Research Center
Louisville, Kentucky, 40213
Lake Health Lyndhurst Clinic
Lyndhurst, Ohio, 44124
Commonwealth Biomedical Research, LLC
Madisonville, Kentucky, 42431
North Georgia Clinical Research
Marietta, Georgia, 30060
Southwind Medical Specialists
Memphis, Tennessee, 38125
Pivotal Research Centers
Midvale, Utah, 84047
Research Institute of the Carolinas, PLLC
Mooresville, North Carolina, 28117
Illinois Bone and Joint Institute, LLC
Morton Grove, Illinois, 60053
Floyd Memorial Hospital
New Albany, Indiana, 47150
HCI Metromedic Walk-In
New Bedford, Massachusetts, 02740
NYU Hospital for Joint Diseases
New York, New York, 10003
BioImaging Technologies, Inc.
Newtown, Pennsylvania, 18940
National Clinical Research - Norfolk, Inc.
Norfolk, Virginia, 23502
Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, 02860
Pivotal Research Centers
Peoria, Arizona, 85381
Arizona Research Center
Phoenix, Arizona, 85023
Pivotal Research Centers
Phoenix, Arizona, 85027
Gold Coast Research, LLC
Plantation, Florida, 33317
Marin E. Hale, M.D., P.A.
Plantation, Florida, 33317
Sabiha Khan, M.D.
Plantation, Florida, 33324
Planters Clinic
Port Gibson, Mississippi, 39150
Rheumatology Associates
Portland, Maine, 04102
National Clinical Research, Incorporated
Richmond, Virginia, 23294
VirtualScopics, Inc.
Rochester, New York, 14625
The Center for Rheumatology and Bone Research
Rockville, Maryland, 20850
Sierra Clinical Research
Roseville, California, 95661
University of California Davis Health System
Sacramento, California, 95817
University of California Davis
Sacramento, California, 95817
PMG Research of Salisbury
Salisbury, North Carolina, 28144
Radiant Research San Antonio Northeast
San Antonio, Texas, 78217
South Texas Radiology Imaging Center
San Antonio, Texas, 78217
Oakwell Clinical Research, LLC
San Antonio, Texas, 78218
Scripps Clinic-Clinical Research
San Diego, California, 92128
Plaza Medical Imaging
Santa Ana, California, 92704
TFD Research, LLC
Shreveport, Louisiana, 71115
The Arthritis Center
Springfield, Illinois, 62704
Advanced Radiology Consultants
Stamford, Connecticut, 06902
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
Piedmont Healthcare/Research
Statesville, North Carolina, 28625
Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York
Syracuse, New York, 13210
Tacoma Center for Arthritis Research, PS
Tacoma, Washington, 98405
New England Research Associates, LLC
Trumbull, Connecticut, 06611
University of Arizona
Tucson, Arizona, 85724
North Mississippi Medical Center, Inc.
Tupelo, Mississippi, 38801
NorthShore University HealthSystem
Vernon Hills, Illinois, 60061
Advanced Pain Management
Virginia Beach, Virginia, 23454
MedVadis Research Corporation
Wellesley Hills, Massachusetts, 02481-2106
Kanner, Mendelson, Shteinman, LLC
West Palm Beach, Florida, 33407
Radiant Research
West Palm Beach, Florida, 33407
Rheumatology and Endocrinology Specialists of the Palm Beaches, P.A.
West Palm Beach, Florida, 33407
The Center for Rheumatology and Bone Research
Wheaton, Maryland, 20902
Heartland Research Associates, LLC
Wichita, Kansas, 67205
Family Medicine East, Chartered/Radiology
Wichita, Kansas, 67207
Heartland Research Associates, LLC
Wichita, Kansas, 67207
Carolina Arthritis Associates, PA
Wilmington, North Carolina, 28401
PMG Research of Wilmington, LLC
Wilmington, North Carolina, 28401
North Georgia Clinical Research
Woodstock, Georgia, 30189
Fallon Clinic, Inc. (Drug Shipment)
Worcester, Massachusetts, 01605
Fallon Clinic, Inc.
Worcester, Massachusetts, 01605
Czechia14 sites
Fakultni nemocnice u sv. Anny v Brne
Brno, 656 91
Revmacentrum MUDr. Mostera, s.r.o.
Brno-Židenice, 615 00
MEDIPONT Plus, s.r.o.
České Budějovice, 370 01
MEDIPONT, s.r.o.
České Budějovice, 370 01
ARTMEDI UPD s r.o.
Hostivice, 253 01
Nemocnice Na Frantisku s poliklinikou
Prague, 11000
Revmatologicky ustav
Prague, 128 50
Centrum pro zdravotnicke zabezpeceni sportovni reprezentace
Prague, 162 00
Ustredni vojenska nemocnice Praha
Prague, 162 00
MSI - Muskuloskeletalni institut
Prague, 169 00
DC Mediscan
Praha 11 - Chodov, 148 00
MediCentrum Praha, a.s.
Praha 11 - Chodov, 148 00
Nemocnice Atlas, a.s.
Zlín, 760 01
PV-Medical s.r.o.
Zlín, 760 01
Peru8 sites
Hospital Nacional "Alberto Sabogal Sologuren" - Essalud
Callao, Provincia Constitucional del Callao, Callao-02
Clínica San Felipe
Lima, Lima Province, L-11
Hospital Nacional "Edgardo Rebagliati Martins" - Essalud
Lima, Lima Province, L-11
Instituto Peruano del Hueso y la Articulación SAC.
Lima, Lima Province, L-27
Hospital Maria Auxiliadora
Lima, Lima Province, L-29
Centro Medico Corpac
Lima, Lima Province, Lima-27
Centro Empresarial - Altavista Polo 4
Santiago de Surco, Lima region, Lima 33
Instituto de Ginecologia y Reproducción & Cirugia Minimamente Invasiva
Santiago de Surco, Lima region, Lima 33
Hungary7 sites
Orszagos Gerincgyogyaszati Kozpont
Budapest, 1126
Synexus Magyarorszag Kft.
Budapest, H-1036
Heves Megyei Onkormanyzat Markhot Ferenc Korhaz
Eger, 3300
Bekes Megyei Kepviselo-testulet Pandy Kalman Korhaz, Reumatologia
Gyula, 5700
Selye Janos Korhaz, Reumatologiai Szakrendelo
Komárom, 2900
MAV Korhaz es Rendelointezet
Szolnok, H-5000
Veszprem Megyei Onkormanyzat Csolnoky Ferenc Korhaz-Rendelointezet
Veszprém, H-8200
Argentina5 sites
OMI - Organización Médica de Investigación
Buenos Aires, C1013AAR
Saint Dennis Medical Group S.A.
Buenos Aires, C1034ACO
Investigaciones Reumatológicas y Osteológicas S.R.L.
Buenos Aires, C1114AAH
Instituto Médico Especializado (IME)
Buenos Aires, C1405BCH
IMAI Research
Buenos Aires, C1425AWC
Germany5 sites
Praxis fuer Orthopaedie, Chirotherapie und Akupunktur
Bad Hersfeld, 36251
Praxis fuer Orthopaedie
Berlin, 12247
Klinische Forschung Berlin-Buch
Berlin, 13125
Praxis Dr. Thomas Jung
Deggingen, 73326
Klinische Forschung Schwerin
Schwerin, 19055
Russia5 sites
Russian State Medical University, Moscow Faculty, City Clinical Hospital #4
Moscow, 115093
Institute of Rheumatology
Moscow, 115522
City Alexandrovskaya Hospital
Saint Petersburg, 193312
L.G. Sokolov Clinical Hospital #122 of Federal Medical-Biology Agency of Russia, Central Polyclinic
Saint Petersburg, 194291
Research Institute of Traumatology and Orthopedy Named After R. R. Vredena
Saint Petersburg, 195427
Canada4 sites
Rheumatology Research Associates Ltd.
Edmonton, Alberta, T5M 0H4
The Arthritis Program Research Group Inc.
Newmarket, Ontario, L3Y 3R7
Centre de Rhumatologie St-Louis
Sainte-Foy, Quebec, G1W 4R4
Nexus Clinic Research
St. John's, Newfoundland and Labrador, A1A 5E8
Italy3 sites
Azienda Sanitaria Genovese, Ospedale La Colletta, Dipartimento Apparato Locomotore
Arenzano, 16011
Presidio Ospedaliero Augusto Murri, Reparto di Reumatologia
Jesi (Ancona), 60035
Ospedale Luigi Sacco, Azienda Ospedaliera Polo Universitario Unita' Operativa di Reumatologia
Milan, 20157
Poland3 sites
NSZOZ "MEDICUS II" S.C. Irena Klimczak, Malgorzata Klimczak, Jerzy Klimczak
Cieszyn, 43-400
"SYNEXUS SCM" Sp. z o.o.
Wroclaw, 50-088
Katedra i Klinika Ortopedii i Traumatologii Narzadu Ruchu
Wroclaw, 50-556
Slovakia3 sites
V. Interna klinika FN a LF UK
Bratislava, 826 06
Ivan Ujvari
Bratislava
Narodny ustav reumatickych chorob
Piešťany, 921 12
Spain3 sites
Hospital General Universitario de Guadalajara
Guadalajara, Guadalajara, 19002
Hospital Ntra. Sra. de La Esperanza
Santiago de Compostela, A Coruña, 15705
Hospital Nuestra Señora de Valme
Seville, Sevilla, 41014
Belgium2 sites
Cliniques Universitaires St Luc
Brussels, 1200
Universitair Ziekenhuis Gasthuisberg / Rheumatology
Leuven, 3000
About this study
Official title: A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study To Investigate The Safety And Efficacy Of Orally Administered SD-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee
The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.
- Conditions
- Osteoarthritis
- Being tested
- SD-6010, Placebo
- Keywords
- knee Osteoarthritis Disease Modifying Osteoarthritis Drug
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SD-6010Drug
200 mg tablets once a day for 2 years
SD-6010Drug
50 mg tablets once a day for 2 years
PlaceboDrug
Placebo tablets once a day for 2 years
| Study group | Role | What they receive |
|---|---|---|
| 200 mg | Active comparator | High dose active comparator Receives: Drug: SD-6010 |
| 50 mg | Active comparator | Low dose active comparator Receives: Drug: SD-6010 |
| Placebo | Placebo comparator | Placebo comparator to be used for control purposes Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Progression of Joint Space Narrowing
Rate of progression of joint space narrowing (JSN) was defined as narrowing in joint space width (JSW) over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in millimeter per year (mm/year) over a 2 year period was used to assess the rate of progression of JSN. Negative values indicating a worsening of osteoarthritis.
Measured: Baseline up to Month 24
Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2
Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.
Measured: Baseline up to Month 24
Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3
Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.
Measured: Baseline up to Month 24
Secondary outcomes (35)
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24
The WOMAC was a self-administered, disease-specific instrument which probed clinically important, participant relevant symptoms in the areas of pain, stiffness, and physical function in participants with OA of the knee. The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 [minimum] to 4 [maximum], higher score indicating worse knee condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Subscale Score at Month 3, 6, 12, 18 and 24
The WOMAC pain subscale was comprised of 5 questions regarding the amount of pain experienced due to OA in the study knee. The WOMAC pain subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse pain. An overall subscale score range of 0 (minimum) to 20 (maximum), with higher scores indicating more pain.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Stiffness Subscale Score at Month 3, 6, 12, 18 and 24
Stiffness was defined as a sensation of decreased ease in which the participant moved the knee with OA. The WOMAC stiffness subscale was comprised of 2 questions regarding the degree of stiffness experienced in the study knee. The WOMAC stiffness subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse stiffness. An overall score range of 0 (minimum) to 8 (maximum), with higher scores indicating more stiffness.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Physical Function Subscale Score at Month 3, 6, 12, 18 and 24
The WOMAC physical function subscale referred to the participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale was comprised of 17 questions regarding the degree of difficulty experienced due to OA in the study knee. The WOMAC physical function subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse physical function. An overall score range of 0 (minimum) to 68 (maximum), with higher scores indicating worse physical function.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Patient Assessment of Arthritic Pain Visual Analog Scale (VAS) Score at Month 3, 6, 12, 18 and 24
Pain VAS was a self-administered instrument, a 100 millimeter (mm) line marked by participant. Intensity of pain range (over past week): 0 (mm) =no pain to 100 (mm) =worst possible pain. Higher score indicating severe pain.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Patient Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using the scale ranging from 1 (minimum) to 5 (maximum), where 1 =very good, 2 =good, 3 =fair, 4 =poor and 5 =very poor. Higher scores indicating worse condition.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Physician's Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24
Physician assessed the overall impact of arthritis on the participant's daily life. Participant's condition was rated by the physician using the scale ranging from 1 (minimum) to 5 (maximum), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicating worse condition.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Pain After a 50-foot Walk Using Pain Visual Analog Scale Score at Month 3, 6, 12, 18 and 24
The pain VAS following a 50 foot walk was a single-item, self-administered instrument. Participants were asked to assess the pain due to OA in their study knee after a 50-foot walk. Participants responded on a VAS scale ranging from 0 (no pain) to 100 (severe pain). Higher scores indicating more pain.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Total Score at Month 3, 6, 12, 18 and 24
The OA pain and assessment tool-knee joint is also known as the intermittent and constant osteoarthritis pain (ICOAP) scale. The OA pain assessment tool-knee joint was an 11-item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. The total score was calculated by adding the 11 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse health.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Constant Pain Subscale Score at Month 3, 6, 12, 18 and 24
The OA pain assessment tool-knee joint constant pain subscale was a 5 item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Overall subscale score was calculated by adding the 5 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse constant pain.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Intermittent Pain Subscale Score at Month 3, 6, 12, 18 and 24
The OA pain assessment tool-knee joint intermittent pain subscale score a 6 item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Overall subscale score was calculated by adding the 6 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse intermittent pain.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Research Society International (OARSI) Knee Function Survey Score at Month 3, 6, 12, 18 and 24
The OARSI knee function survey was an 11-item scale with each item scored 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. The total score was the sum of the 11 items and ranged from 0 (minimum) to 44 (maximum), where higher scores indicating worse health condition.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score - Physical Function Short Form (KOOS-PS) Score at Month 3, 6, 12, 18 and 24
The KOOS-PS was used to rate participant's opinions about the difficulties they experienced with activity due to problems with their knee. It was a 7-item scale, each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Total score was calculated by adding the responses to 7 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse health condition.
Measured: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Short Form-36 (SF-36) Physical Functioning Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 16.18 (minimum) to 57.11 (maximum), with higher scores indicating better physical functioning.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Role - Physical Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 18.45 (minimum) to 56.62 (maximum), with higher scores indicating better role-physical.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Bodily Pain Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 19.23 (minimum) to 60.88 (maximum), with higher scores indicating lower bodily pain.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 General Health Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 16.75 (minimum) to 63.72 (maximum), with higher scores indicating better general health.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Vitality Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 22.02 (minimum) to 69.92 (maximum), with higher scores indicating better vitality.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Social Functioning Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 13.38 (minimum) to 56.40 (maximum), with higher scores indicating better social functioning.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Role-Emotional Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 10.25 (minimum) to 55.68 (maximum), with higher scores indicating better role-emotional.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Mental Health Domain Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 8.02 (minimum) to 63.43 (maximum), with higher scores indicating better mental health.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Physical Health Component Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 22.88 (minimum) to 58.69 (maximum), with higher scores indicating better physical health.
Measured: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Mental Health Component Score at Month 12 and 24
The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 11.11 (minimum) to 61.67 (maximum), with higher scores indicating better mental health.
Measured: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D (EQ-5D) Mobility Domain Score
EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D mobility domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problem), 2 =moderate health (some problems) and 3 =worst health (confined to bed). Higher scores indicating worse health condition. Participants with EQ-5D mobility domain score were reported in this measure.
Measured: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Self-Care Domain Score
EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D self-care domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problems with self-care), 2 =moderate health (some problems) and 3 =worst health (unable to wash or dress). Higher scores indicating worse health condition. Participants with EQ-5D self-care domain score were reported in this measure.
Measured: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Usual Activity Domain Score
EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D usual activity domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problems), 2 =moderate health (some problems) and 3 =worst health state (unable to perform usual activities). Higher scores indicating worse health condition. Participants with EQ-5D usual activity domain score were reported in this measure.
Measured: Baseline, Month 12, 24
Number of Participants With EuroQo-5D Pain and Discomfort Domain Score
EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D pain and discomfort domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no pain and discomfort), 2 =moderate health (moderate pain and discomfort) and 3 =worst health state (extreme pain and discomfort). Higher scores indicated worse health condition. Participants with EQ-5D pain and discomfort domain score were reported in this measure.
Measured: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Anxiety and Depression Domain Score
EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. EQ-5D anxiety and depression domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (not anxious, depressed), 2 =moderate health (moderately anxious, depressed) and 3 =worst health (extremely anxious, depressed). Higher scores indicating worse health condition. Participants with EQ-5D anxiety and depression domain score were reported in this measure.
Measured: Baseline, Month 12, 24
EuroQoL-5D Visual Analog Scale Score
The EQ-5D VAS score was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.
Measured: Baseline, Month 12, 24
Number of Participants With Increase in Total Analgesic Medication Use
Increase in total analgesic medication use for OA in the study knee was a comparison back to baseline of an increased and sustained use of standard background and/or rescue medication for more than 28 days as measured at the Month 12 and 24 visits. Only medications for OA knee pain were considered.
Measured: Month 12, 24
Number of Participants With Decrease in Total Analgesic Medication Use
Decrease in total analgesic medication use for OA in the study knee was a comparison back to baseline of a decreased and irregular use of standard background and/or rescue medication for more than 28 days as measured at the Month 12 and 24 visits. Only medications for OA knee pain were considered.
Measured: Month 12, 24
Patient Global Impression of Change Score
Patient global impression of change was a participant-rated instrument that measured change in participant's overall status on a 7-point scale ranging from: 1 =very much improved, 2 =much improved, 3 =minimally improved, 4 =no change, 5 =minimally worse, 6 =much worse and 7 =very much worse. Higher scores indicating worse condition.
Measured: Month 24
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index
The OMERACT-OARSI responder index was used to determine whether participants may be considered responders to treatment. An OMERACT-OARSI responder was a participant who had a better response on the WOMAC pain subscale score, a better response on the WOMAC physical function subscale score or improvement on at least two of the three domains: WOMAC pain subscale score (overall score range of 0 [minimum] to 20 [maximum], higher scores indicating more pain), WOMAC physical function subscale score (overall score range of 0 [minimum] to 68 [maximum], higher scores indicating worse physical function) and patient global assessment of arthritic condition score (overall score range of 1 [minimum] to 5 [maximum], higher scores indicating worse condition). Number of participants who were OMERACT-OARSI responder were reported in this measure.
Measured: Month 24
Number of Participants With Joint Space Narrowing Progression
JSN progressor was defined as a participant with a decrease in joint space width that was greater in magnitude than the smallest detectable difference (0.199 mm).
Measured: Month 24
Number of Participants Applicable for Virtual Joint Replacement
A virtual joint replacement candidate was defined as a participant whose last two WOMAC pain subscale scores (overall score range of 0 [minimum] to 20 [maximum], higher scores indicating more pain) were at least 8, last two WOMAC physical function subscale scores (overall score range of 0 [minimum] to 68 [maximum], higher scores indicating worse physical function) were at least 28 and was a joint space narrowing progressor (a participant with a decrease in JSW that was greater in magnitude than the smallest detectable difference =0.199 mm).
Measured: Month 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2007 (estimated)
- Study startNov 2007
- Primary completionOct 2011
- Study completionNov 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 1,457 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00565812
- Sponsor's protocol ID
- A6171016
- Other IDs
- 2007-001457-26, ITIC
- Acronym
- ITIC
- Status last verified
- Nov 2016
- First submitted
- 29 Nov 2007
- Last updated
- 30 Dec 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, Abramson SB, Manning PT, Miller CG, Vignon E. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. doi: 10.1136/annrheumdis-2012-202239. Epub 2012 Nov 10.
PubMed 23144445
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study To Investigate The Safety And Efficacy Of Orally Administered SD-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee
- ClinicalTrials.gov ID
- NCT00565812
- Acronym / sponsor ID
- ITIC / A6171016
- Conditions
- Osteoarthritis
- Keywords
- knee Osteoarthritis Disease Modifying Osteoarthritis Drug
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,457 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Nov 2007
- Primary completion
- Oct 2011 (actual)
- Study completion
- Nov 2011 (actual)
- First posted
- 30 Nov 2007 (estimated)
- Results
- Posted 30 Dec 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 200 mg | Active comparator | Drug: SD-6010High dose active comparator |
| 50 mg | Active comparator | Drug: SD-6010Low dose active comparator |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo comparator to be used for control purposes |
Who may qualify
- Ages
- 40 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Subjects aged >= 40 years with a BMI >= 25 and <= 40 kg/m2
- In the past, has been diagnosed with knee OA
- Radiographic evidence of OA in the study knee
Key exclusion criteria (3 listed)
- A diagnosis of any other rheumatic disease
- Current conditions in the study knee that would confound efficacy
- Selected, traditional clinical safety and laboratory parameters
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SD-6010200 mg tablets once a day for 2 years | Drug | 200 mg |
| SD-601050 mg tablets once a day for 2 years | Drug | 50 mg |
| PlaceboPlacebo tablets once a day for 2 years | Drug | Placebo |
Primary outcome
Rate of Progression of Joint Space Narrowing
Time frame: Baseline up to Month 24
Rate of progression of joint space narrowing (JSN) was defined as narrowing in joint space width (JSW) over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in millimeter per year (mm/year) over a 2 year period was used to assess the rate of progression of JSN. Negative values indicating a worsening of osteoarthritis.
Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2
Time frame: Baseline up to Month 24
Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.
Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3
Time frame: Baseline up to Month 24
Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.
35 secondary outcomes
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Subscale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Stiffness Subscale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Physical Function Subscale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Patient Assessment of Arthritic Pain Visual Analog Scale (VAS) Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Patient Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Physician's Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Pain After a 50-foot Walk Using Pain Visual Analog Scale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Total Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Constant Pain Subscale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Intermittent Pain Subscale Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Osteoarthritis Research Society International (OARSI) Knee Function Survey Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score - Physical Function Short Form (KOOS-PS) Score at Month 3, 6, 12, 18 and 24
Time frame: Baseline, Month 3, 6, 12, 18, 24
Change From Baseline in Short Form-36 (SF-36) Physical Functioning Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Role - Physical Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Bodily Pain Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 General Health Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Vitality Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Social Functioning Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Role-Emotional Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Mental Health Domain Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Physical Health Component Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Change From Baseline in Short Form-36 Mental Health Component Score at Month 12 and 24
Time frame: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D (EQ-5D) Mobility Domain Score
Time frame: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Self-Care Domain Score
Time frame: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Usual Activity Domain Score
Time frame: Baseline, Month 12, 24
Number of Participants With EuroQo-5D Pain and Discomfort Domain Score
Time frame: Baseline, Month 12, 24
Number of Participants With EuroQoL-5D Anxiety and Depression Domain Score
Time frame: Baseline, Month 12, 24
EuroQoL-5D Visual Analog Scale Score
Time frame: Baseline, Month 12, 24
Number of Participants With Increase in Total Analgesic Medication Use
Time frame: Month 12, 24
Number of Participants With Decrease in Total Analgesic Medication Use
Time frame: Month 12, 24
Patient Global Impression of Change Score
Time frame: Month 24
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index
Time frame: Month 24
Number of Participants With Joint Space Narrowing Progression
Time frame: Month 24
Number of Participants Applicable for Virtual Joint Replacement
Time frame: Month 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 23144445Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, Abramson SB, Manning PT, Miller CG, Vignon E. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. doi: 10.1136/annrheumdis-2012-202239. Epub 2012 Nov 10.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Osteoarthritis
RecruitingPhase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Knee Cartilage Defects
Recruiting
The Effect of Different Exercise Training Programs on Muscle Oxygenation in Individuals With Knee Osteoarthritis
Osteoarthritis of Knee
Not yet recruiting
Comparison of Telerehabilitation and Usual Rehabilitation After Knee or Hip Surgery
Orthopedic Surgery, Rehabilitation
Not yet recruiting
Comparison of High-Intensity and Conventional Physical Therapy in Musculoskeletal Disorders
Low Back Pain, Radicular Syndrome
Recruiting
Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.
Knee Osteoarthritis, Replacement, Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
183 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SD-6010 in people with Osteoarthritis, run by Pfizer at 183 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 183 sites in United States, Czechia, Peru, Hungary, Argentina and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Dec 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Progression of Joint Space Narrowing (time frame: Baseline up to Month 24). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00565812, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2016.